BioXcel Therapeutics (BTAI) Tops Q3 EPS by 19c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($0.32), $0.19 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Adecoagro S.A. (AGRO) Misses Q2 EPS by 63c
• Chicago Atlantic Real Estate Finance (REFI) PT Lowered to $16 at Citizens Post Q2 Results